What is the mission of P2T?
Simple: P2T wants to develop new drugs and devices quickly and cheaply.
But, is this not happening already?
No, the development of a new drug or device still takes years. The drugs developed are expensive and usually have serious side effects.
Why would P2T be better in developing new drugs and devices quicker and cheaper?
- P2T consists of a group of twelve board certified specialists/medical investigators, which at the end of their carriers are willing to perform clinical/medical research without a profit motive.
- P2T has written projects for 4 new treatment methods/drugs, who have not yet been investigated in patients, but are promising better efficacy and less side effects.
- P2T honors its name by only doing short lasting phase2 studies. In approximately 30 patients we will observe whether the new drug/treatment has a beneficial effect in at least 1 out of 3 patients without inducing serious side effects. If this is indeed the case further development will be pursued. If not, P2T will stop the study and report its negative result in the open medical literature.
Has the pharmaceutical Industry no interest in the projects of P2T because they are in fact not very promising?
No, the pharmaceutical industry will only develop new drugs, which generate substantial profits. Their Shareholders expect their stocks to increase in value each year.
Where does P2T do its clinical medical research?
P2T collaborators are located in The Netherlands, Great Britain, Lebanon and the United States. The first four P2T projects will be initiated in The Netherlands.
How can a not for profit organization, like P2T, raise sufficient funds to finance their projects?
By way of grant applications, donations, and crowd sourcing.